Welgen

Executive Summary

Welgen is a privately held diagnostics company specializing in the production and purification of recombinant adenoviral vectors. Founded in 2002 and headquartered in Worcester, Massachusetts, the company offers custom amplification and purification services to deliver high-titer viral stocks (up to 1×10¹² viral particles/mL) via cesium chloride gradient centrifugation. Welgen serves customers requiring both small-scale and large-scale adenovirus preparations for research and preclinical applications. Despite a limited public profile and no disclosed funding or revenue, the company's two-decade operating history suggests niche expertise and a stable client base in the gene therapy and vaccine development sectors. Welgen's services are critical for researchers needing consistent, high-quality viral vectors for translational studies. However, the lack of recent news, financial disclosures, or pipeline visibility constrains assessment of its market position and growth trajectory. The company remains a specialized contract service provider in the competitive viral vector manufacturing landscape.